AngioDynamics Q1 2027: EPS Beat Powered by a Margin Surge
As seen on the 24/7 Wall St. homepage on October 8, 2026.
The quarterly loss came in at a third of what analysts expected as gross margin expanded 410 basis points to 59.4%. Full-year sales guidance of $336 million to $341 million stays intact ahead of Eric Honroth taking over as CEO in November.
Continue ReadingShow less
AngioDynamics beat expectations with an adjusted loss of just $0.04 per share, and the reason to care is margin: gross margin expanded 410 basis points to 59.4% on better pricing and a shift toward higher-margin products.
The Med Tech segment drove the quarter, with revenue up 13.2% year over year on strength in NanoKnife, Auryon and AlphaVac.
Revenue rose 6.9% year over year, ahead of estimates, and management held full-year fiscal 2027 guidance steady while expecting positive operating cash flow.
Management expects gross margin to soften in the second half of fiscal 2027, CEO Jim Clemmer retires in November with Eric Honroth taking over, and FDA IDE approval for the RELIEF study extends NanoKnife beyond oncology.
Mentioned: ANGO